Thazolidinediones: Which future in the treatment of type 2 diabetes?;Les thiazolidinediones: Quel avenir dans le traitement du diaèbte de type 2?

Medecine et Hygiene

Volumn 56, Issue 2219, 1998, Pages 1574-1578

  Scheen, A J ^a   Poquot, N ^a   Letiexhe, M R ^a   Lefebvre P J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; METFORMIN; SULFONYLUREA; TROGLITAZONE;

DIETARY INTAKE; DISEASE ASSOCIATION; FOOD AND DRUG ADMINISTRATION; HEPATITIS; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; REVIEW; SYNDROME X;

EID: 0032581807     PISSN: 00256749     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Scheen AJ, Paquot N, Lefehvre PJ. Etiologie et physiopathahgie du diebete non insulino dependent. Encyclopédie médico-chirurgicale (Paris-France). Endocrinologie-Nutrition 1995; 10-366-D-10:7 p.
2. Scheen AJ, Lefèbvre PJ. Pathophysiology of type 2 diabetes. In : Kuhlmann J, Puls W, editors. Handbook of experimental pharmacology, oral antidiabetics. Berlin : Springer Verlag, 1996: 7-42.
3. Scheen AJ, Paquot N, Lefèbvre PJ. Approches thérapeutiques des anomalies de la boucle de régulation glucose-insuline chez le patient diabétique. Méd et Hyg 1992; 50: 2088-93.
4. Lefèbvre PJ, Scheen AJ. Improving the action of insulin. Clin Invest Med 1995; 18:340-7.
5. Reaven CM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607.
6. DeFronzo RA, Ferrannini E. Insulin resistance : A mutltifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14:173-94.
7. Scheen AJ. Le syndrome plurimétabolique associé à l'insulinorésistance ou syndrome X: actualisation après 10 ans. Diabétologie et Facteurs de Risque 1997; 3: 254-8.
8. Scheen AJ. Drug treatment of noninsulin-dependent diabetes mellitus in the 1990s: Achievements and future developments. Drugs 1997; 54: 355-68.
9. Scheen AJ, Lefèbvre PJ. La metformine : des effets métaboliques aux indications thérapeutiques. Méd et Hyg 1993; 51: 1993-8.
10. Scheen AJ, Paquot N, Letiexhe MR. Lefèbvre PJ. A propos de quelques utilisations non conventionnelles de la metformine. Méd et Hyg 1997; 55: 1492-4.
11. Irzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998; 338: 867-72.
12. Hofmann CA, Colca JR. New oral azolidinedione antidiabetic agents act as insulin sensitizers: Diabetes Care 1992; 15: 1675-8.
13. Henry RR. Thidinedioms. Endocrinol Metab Clin North Am 1997; 26: 553-73.
14. Kaneko T. Troglitazone (CS-045): A new antidiabetic agent. Horm Metab Res 1997; 29: 203-13.
15. Spencer CM, Markham A. Troglitaznne. Drugs 1997; 54: 89-101.
16. Saltiel AR, Okfsky JM. Thiazolidinediones in the treatment of insulin resistante and type II diabetes. Diabetes 1996; 45: 1661-9.
17. Spiegelman BM. PPAR-gamma : Adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47: 507-14.
18. Nolan JJ, Ludvik B, Beerdsen P, et al. Improvement in glucose tole- rance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994; 131: 1188-93.
19. Antonucci T, Whitcomb R, McLain K, Lockwood D. Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone. Diabetes Care 1997; 20: 188-93.
20. Berkawitz K, Peters R, Kjos SL, et al. Effect of troglitazone on insulin sensitivity and pancreatic B-cell function in women at high risk for NIDDM. Diabetes 1996; 45: 1572-9.
21. Mimura K, Umeda A, Hiramatsu S, et al. Effects of a new oral hypoglycaemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes. Diabetic Med 1994; 11: 685-91.
22. Petrie J, Small M, Connell J. «Glitazones», a prospect for non-insnlin-dependent diabetes. Lancet 1997; 349: 70-1.
23. Scheen AJ, Lefebvre PJ. Oral antidiabetic agents: A guide to selection. Drugs 1998; 55: 225-36.
24. Kumar S, Boulton AJM, Beck-Nielsen H, et al for the Troglitazone study group. Troglitazone. an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetohgia 1996; 39: 701-9.
25. Iwamoto Y, Kosaka K, Kuzuya T, et al. Effect of combination therapy of troglitazone and stdphonylureas in patients with type 2 diabetes who were poorly controlled by sulphonylurea therapy alone. Diabetic Med 1996; 13: 365-70.
26. Schwartz S, Raskin P, Fonseca V, et al. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. N Engl J Med 1998; 338: 861-6.
27. Ghazzi MN, Perez JE, Antonucci TK, et al. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes 1997; 46: 433-9.
28. Prigeon RL, Kahn SE, Porte D Jr. Effect of troglitazone on B cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 1998; 83: 819-23.
29. Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med 1998; 338: 916-7.
30. Imura H. A novel antidiabetic drug, troglitazone - reason for hope and concern. N Engl J Med 1998; 338: 908-9.